Systemic sclerosis-associated interstitial lung disease (SSc-ILD) requires accurate diagnosis and staging to identify patients with the highest risk of disease progression, who might benefit from treatment with immunosuppressants. New insights into predictors of mortality in patients with SSc-ILD should improve patient care and inform the design of future clinical trials.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Al-Dhaher, F. F., Pope, J. E. & Ouimet, J. M. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin. Arthritis Rheum. 39, 269–277 (2010).
Tyndall, A. J. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann. Rheum. Dis. 69, 1809–1815 (2010).
Lefevre, G. et al. Survival and prognositic factors in systemic-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 65, 2412–2423 (2013).
Tashkin, D. P. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354, 2655–2666 (2006).
Hoyles, R. K. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54, 3962–3970 (2006).
Tashkin, D. P. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomized controlled trial. Lancet Respir. Med. 4, 708–719 (2016).
Goh, N. S. et al. Short term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. http://dx.doi.org/10.1002/art.40130 (2017).
Silver, R. M. et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J. Rheumatol. 20, 838–844 (1993).
Roth, M. D. et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum. 63, 2797–2808 (2011).
Khanna, D. et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res. Ther. 17, 372 (2015).
Acknowledgements
R.M.S. would like to acknowledge support from the following funding sources; the NIH/ US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (grant numbers R21AR065089 and P60AR062755); the Patient-Centered Outcomes Research Institute (PCORI); and South Carolina Smart State.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Silver, R. Choosing patients wisely when treating interstitial lung disease. Nat Rev Rheumatol 13, 455–456 (2017). https://doi.org/10.1038/nrrheum.2017.103
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.103
